McIntyre Peter B, Turnbull Fiona M, Egan Anne-Marie, Burgess Margaret A, Wolter Joanne M, Schuerman Lode M
Centre for Immunisation Research, University of Sydney and the Royal Alexandra Hospital for Children, Locked Bag 4001, Westmead, NSW 2145, Australia.
Vaccine. 2004 Dec 2;23(3):380-5. doi: 10.1016/j.vaccine.2004.05.030.
There is increasing interest in prevention of pertussis in adults by vaccination, but little is known about the duration of the antibody response to pertussis, diphtheria or tetanus in reduced antigen content vaccines formulated for adult use. Follow-up of a clinical trial including 550 adults comparing responses to reduced antigen content diphtheria-tetanus-acellular pertussis (dTpa) vaccine, or a licensed Td vaccine, provided the opportunity to evaluate this. Blood samples were collected at 0, 1, 12, 24 and 36 months following vaccination; of the original cohort of 550, 387 subjects (dTpa group N=310, Td+pa group N=77) were tested at month 36. Following a decrease in antibody levels against all vaccine antigens between one and 24 months following vaccination, levels stabilized during the third year, remaining higher at 36 months than pre-vaccination for all vaccine antigens. In particular, more than 90% of subjects remained seropositive for pertussis toxin and pertactin antibodies at 36 months after vaccination, suggesting ongoing protection against pertussis. Adult-formulated dTpa vaccines could replace Td for routine booster vaccination of older individuals.
通过接种疫苗预防成人百日咳越来越受到关注，但对于为成人使用而配制的抗原含量降低的疫苗中，针对百日咳、白喉或破伤风的抗体反应持续时间知之甚少。一项包括550名成年人的临床试验随访，比较了对抗原含量降低的白喉-破伤风-无细胞百日咳（dTpa）疫苗或已获许可的Td疫苗的反应，为评估这一点提供了机会。在接种疫苗后的0、1、12、24和36个月采集血样；在最初的550名受试者队列中，387名受试者（dTpa组N = 310，Td + pa组N = 77）在36个月时接受了检测。在接种疫苗后1至24个月期间，针对所有疫苗抗原的抗体水平下降后，在第三年水平稳定，在36个月时所有疫苗抗原的抗体水平仍高于接种前。特别是，超过90%的受试者在接种疫苗后36个月时百日咳毒素和百日咳杆菌粘附素抗体仍呈血清阳性，表明对百日咳有持续的保护作用。成人用dTpa疫苗可替代Td用于老年人的常规加强免疫接种。
